Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.02 from other evidence | 0.00 |
| cell type Human Protein Atlas | cell type enhanced outside the brain (t-cells) | 0.10 |
| chemistry Open Targets | compounds already reach it: dasatinib anhydrous, jnj-26483327, xl-228 +5 | 1.00 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | 9 Parkinson's papers of 3,460 | 0.70 |
| pathways Reactome | 23 pathways; mostly dopamine synapse | 1.00 |
No case: the score is under the bar. Receipt 7617
Sealed predictions
- LCK in dopamine neurons, braak+0.16 (p 0.685) → -0.52 (p 0.153)receipt 7625
Swarm cases
receipt 7625: LCK in dopamine neurons, braak
- power
- full sample -0.03 (p 0.922, n 18), 95% CI -0.49 to +0.45. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.03 (p 0.908, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.05 (p 0.847, n 18). could be the mix.
- skeptic
- leave-one-out range -0.13 to +0.11, sign flips 8; without severely affected donors -0.03 (p 0.922, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for LCK in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts